Airway Clearance study
Study identifier:D5892C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomized, double-blind, two-way cross-over study evaluating systemic bioavailability and airway clearance of SymbicortTurbuhaler 320/9mcg vs SeretideDiskus 50/500mcg after single inhalations in patients with COPD and healthy volunteers
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
Phase 4
Healthy volunteers
Yes
Study drug
Budesonide/Formoterol Turbuhaler, Salmeterol/Fluticasone Diskus
Sex
All
Actual Enrollment
54
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2006
Primary Completion Date: -
Study Completion Date: 01 Jul 2007
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Christer Hultquist
AstraZeneca
